1. Volume 13, Issue 11, Pages 1161-1170 (November 2012)
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial 
Prof Siow Ming Lee, MD, Iftekhar Khan, MSc, Sunil Upadhyay, MD, Conrad Lewanski, FRCP, Stephen Falk, MD, Geraldine Skailes, FRCR, Ernie Marshall, MD, Prof Penella J Woll, FRCP, Matthew Hatton, FRCR, Rohit Lal, MRCP, Richard Jones, FRCR, Elizabeth Toy, FRCR, David Chao, DPhil, Gary Middleton, MD, Sue Bulley, SRN, Yenting Ngai, BSc, Robin Rudd, MD, Prof Allan Hackshaw, MSc, Prof Chris Boshoff, MD 
The Lancet Oncology 
Volume 13, Issue 11, Pages (November 2012)
DOI: /S (12)
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Patients with no recorded start date of study drug or dosing details. ECOG=Eastern Cooperative Oncology Group performance status. CRCL=creatinine clearance.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

3. Figure 2
Overall survival and progression-free survival for all patients
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

4. Figure 3
Overall survival and progression-free survival according to whether patients on erlotinib developed first-cycle rash or not
HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions